Tempo Therapeutics Inc
San DIego, CA · CIK 0001813688 · Biotech · Private
Novel vaccine platform technology for rapid development of vaccines against emergent pathogens, initially targeting SARS-CoV-2 variants
tempothera.com →- Grants
- $10M
- 11 awards
- Sector median: 1
- Raised
- $34M
- 3 Form D · Sep 2026
- 1 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 14
- 2 granted · 12 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201620182020202220242026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · A flowable microporous biomaterial as a low cost, high efficacy diabetic chronic ulcer treatment | $224,999 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · A flowable microporous biomaterial as a low cost, high efficacy diabetic chronic ulcer treatment | $224,999 | |
| Federal grant | Department of Health and Human Services · Phase II · MAP: a Flowable, Precision-Engineered, and Tunable Tissue Scaffold Leveraging Hyper-Porous Geometry to Control Inflammation and Promote Regenerative Healing in Diabetic Wounds | $737,053 | |
| Federal grant | Department of Health and Human Services · Phase II · MAP: a Flowable, Precision-Engineered, and Tunable Tissue Scaffold Leveraging Hyper-Porous Geometry to Control Inflammation and Promote Regenerative Healing in Diabetic Wounds | $1,598,652 | |
| Federal grant | National Science Foundation · Phase I · SBIR Phase I: A new vaccine technology to engineer a potent and polarized immunity against COVID-19 | $255,998 | |
| Federal grant | Department of Health and Human Services · Phase II · Diversity supplement for Oliver Viyar to receive research training in tissue engineering. | $24,685 | |
| Private capital raised | Form D · SEC | $3,844,046 | |
| Federal grant | Department of Health and Human Services · Phase II · MAP: a Flowable, Precision-Engineered, and Tunable Tissue Scaffold Leveraging Hyper-Porous Geometry to Control Inflammation and Promote Regenerative Healing in Diabetic Wounds | $836,914 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · A first in human clinical study of TT101, a synthetic immunomodulatory material to build new functional tissue over exposed bone as a one time treatment for diabetic limb preservation patients | $1,368,090 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · A first in human clinical study of TT101, a synthetic immunomodulatory material to build new functional tissue over exposed bone as a one time treatment for diabetic limb preservation patients | $2,549,496 | |
| Federal grant | Department of Health and Human Services · Phase II · A first in human clinical study of TT101, a synthetic immunomodulatory material to build new functional tissue over exposed bone as a one time treatment for diabetic limb preservation patients | $1,181,406 | |
| Federal grant | National Science Foundation · Phase II · STTR Phase II:VaxMAP a single dose multivalent vaccine to produce durable and cross-reactive immunity against various coronaviruses | $1,000,000 | |
| Private capital raised | Form D · SEC | $16,327,664 | |
| Private capital raised | Form D · SEC | $14,000,000 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1746 | INFINIFLUIDICS INC | — | — |
| 1747 | Airway Therapeutics, LLC | — | $54M |
| 1748 | Quoin Pharmaceuticals, Ltd. | — | $164M |
| 1749 | Tempo Therapeutics Inc | — | $34M |
| 1750 | ASAKE BIOTECHNOLOGY, LLC | — | — |
| 1751 | ANTHROBIO, INC. | — | — |
| 1752 | Torque Medical Holdings, LLC | — | $4.7M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Dino Di CarloDirector
- Donald GriffinDirector
- Richard HancockDirector
- Biren MehtaDirector
- Steven RichieriDirector · Executive Officer
- Steven SandsDirector
- Robin SitverDirector
- Westbrook WeaverDirector · Executive Officer · Promoter
Patents
- Annealed Microgel Particle Systems And Methodsapplication
- Methods Of Manufacturing Injectable Microgel Scaffoldsapplication
- Methods Of Manufacturing Injectable Microgel Scaffoldsapplication
- Systems To Promote Healing At A Site Of A Medical Deviceapplication
- Methods Of Manufacturing Injectable Microgel Scaffoldsgranted
- Systems To Promote Healing At A Site Of A Medical Devicegranted
- Methods For Treating Or Preventing Fibrosis At A Site Of A Medical Implantapplication
- Hydrogel Formulations And Methods Of Use Thereofapplication
- Methods And Systems For Treating A Site Of A Medical Implantapplication
- Annealed Microgel Particle Systems And Methodsapplication
- Methods And Systems For Treating A Site Of A Medical Implantapplication
- Hydrogel Formulations And Methods Of Use Thereofapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.